Alkermes Starts RMP-7 Efficacy Trials
Alkermes has started the first of three Phase II trials of its blood brain barrier permeation enhancer RMP-7, administered in combination with carboplatin, for the treatment of recurrent glioma. The first study is being conducted in the UK at up to six hospitals and will involve up to 50 patients. Endpoints are tumor response and clinical status.
The study follows the completion of preliminary analysis of two Phase I/II safety studies of RMP-7 and carboplatin and a Phase I trial showing RMP-7's effect on increasing brain tumor permeability to a pharmaceutical compound. RMP-7 is believed to act by triggering relaxation of endothelial tight junctions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze